|Year : 2016 | Volume
| Issue : 5 | Page : 37-42
Adjuvant therapy with heparin in patients with lung cancer without indication for anticoagulants: A systematic review of the literature with meta-analysis
Yuman Yu1, Qun Lv1, Bin Zhang2, Fen Lan2, Yifan Dai1
1 Department of Pulmonary Medicine, Hangzhou Normal University, The Affiliated Hospital of Hangzhou Normal University, Hangzhou 310015, Zhejiang, China
2 Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, Institute of Respiratory Diseases, Zhejiang University School of Medicine, Hangzhou, China
|Date of Web Publication||7-Oct-2016|
Department of Pulmonary Medicine, Hangzhou Normal University, The Affiliated Hospital of Hangzhou Normal University, Hangzhou 310015, Zhejiang
Source of Support: None, Conflict of Interest: None
Background: The effect of heparin in improving cancer survival has gained increasing attention over the past decades. Several clinical trials have evaluated the role of heparin on survival outcome and its safety profile in lung cancer patients. Thus, we performed a systematic review and meta-analysis from the results of randomized controlled trials (RCTs) to assess the efficacy and safety of heparin in patients with lung cancer without indication for anticoagulants.
Methods: We searched PubMed, Embase, and The Cochrane Central Register of Controlled Trials databases for relevant studies. The inclusion criteria used were patients with lung cancer without a concurrent diagnosis of venous thromboembolism (VTE) and were treated with low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH). The outcomes included survival outcome, VTE, bleeding, major bleeding, and thrombocytopenia. The results were presented as hazard ratio (HR) and relative risk (RR), and the STATA 12.0 package was used for comprehensive quantitative analysis.
Results: A total of 6 studies with 753 cases and 640 controls were included for the final analysis. The meta-analysis showed significant differences in survival with an HR of 0.71 (95% confidence interval [CI] 0.60–0.84), particularly in limited-stage small cell lung cancer (SCLC) with an HR of 0.57 (95% CI 0.43–0.77), and also in VTE (RR 0.46; 95% CI 0.27–0.80) when heparin was compared with placebo or no anticoagulant. There were no significant differences in risks for bleeding (RR 1.53; 95% CI 0.96–2.45), major bleeding (RR 1.43; 95% CI 0.59–3.45), and thrombocytopenia (RR 0.86; 95% CI 0.66–1.12).
Conclusion: Administration of heparin (mainly LMWH) as primary thromboprophylaxis for lung cancer patients without indication for anticoagulants was associated with a significant survival benefit, particularly in limited-stage SCLC.
Keywords: Anticoagulants, heparin, lung cancer, systematic review
|How to cite this article:|
Yu Y, Lv Q, Zhang B, Lan F, Dai Y. Adjuvant therapy with heparin in patients with lung cancer without indication for anticoagulants: A systematic review of the literature with meta-analysis. J Can Res Ther 2016;12, Suppl S1:37-42
|How to cite this URL:|
Yu Y, Lv Q, Zhang B, Lan F, Dai Y. Adjuvant therapy with heparin in patients with lung cancer without indication for anticoagulants: A systematic review of the literature with meta-analysis. J Can Res Ther [serial online] 2016 [cited 2021 Sep 26];12:37-42. Available from: https://www.cancerjournal.net/text.asp?2016/12/5/37/191627
| > Introduction|| |
Worldwide, lung cancer accounts for approximately 1.6 million new cases of cancer and 1.4 million of cancer-related death annually. Lung cancer is associated with a poor prognosis. For non-small cell lung cancer (NSCLC), which is the most frequent histological type of lung cancer, the overall 5-year survival rate is 18.2%. The prognosis is even poorer in SCLC, which has an overall 5-year survival rate of 6.3%. Long-term survival for lung cancer patients remains a tremendous challenge, and there is an urgent need for new approaches to enhance our current therapeutic approaches.
The association between venous thromboembolism (VTE) and cancer has been convincingly demonstrated since Trousseau's initial observations in 1865. The overall risk of VTE is increased 7-fold in patients with a malignancy than persons without malignancy, and this risk is further increased by chemotherapy, surgery, and disease progression., In patients with lung cancer, even a 22-fold increased risk was observed. On the other hand, VTE in cancer patients predicts a poor prognosis., The occurrence of cancer-associated thrombosis presents a dilemma for the physician, especially in patients with metastatic disease. Thence preventing VTE in patients with cancer may improve cancer survival.
Due to the importance of thromboprophylaxis in cancer patients, numerous studies have been conducted to explore the impact of anticoagulants on cancer survival. It seems that heparin is superior to warfarin in cancer patients in terms of increased efficacy with a good safety profile and reliability and is also associated with improved quality of life.
Besides its antithrombosis property in cancer, heparin also exhibits a potential anticancer effect. The anticancer mechanism of heparin remains unclear. It has been reported that heparin possesses direct antitumor effects, anti-angiogenic effects, and immunomodulatory effects. Heparin also enhances antitumor effects of chemotherapeutic agents.,
Several studies have evaluated the role of heparin on survival outcome and safety profile in lung cancer patients. Three small-scale studies have indicated that adjuvant therapy with heparin may be associated with a survival benefit in SCLC patients.,, Nevertheless, a randomized clinical trial examining the effect of nadroparin on survival cancer patients did not show a survival benefit of nadroparin in cancer patients, neither in the NSCLC subgroup. However, most of these trials were too small to reliably detect moderate treatment effects.
Consequently, the survival outcome and safety of heparin in lung cancer patients remains inconclusive owing to the limited sample size and inconsistent results of these individual studies. We, therefore, conduct a systematic literature review and meta-analysis of six randomized controlled trials (RCTs) concerning this subject. The purpose of our study was to determine the efficacy and safety of heparin on survival in patients with lung cancer.
| > Methods|| |
We performed a comprehensive literature search in the PubMed, Embase, and The Cochrane Central Register of Controlled Trials databases. The terms (tumor OR malign * OR carcinoma * OR cancer OR SCLC OR non-SCLC OR NSCLC OR neoplasm*) AND (heparin OR low molecular weight heparin OR LMWH OR enoxaparin OR dalteparin OR reviparin OR certoparin OR tinzaparin OR bemiparin OR nadroparin OR * parin) were used. We scanned references of all included trials and reviews for additional studies. In addition, we searched databases of ongoing and unpublished trials on line (http://www.clinicaltrials.gov).
We included RCTs that compared the addition of LMWH or unfractionated heparin (UFH) to standard chemotherapy in lung cancer patients without a concurrent diagnosis of VTE as primary thromboprophylaxis. To ensure an adequate amount of therapeutic time, LWMH or UFH had to be given for at least 4 weeks without interruption. The primary efficacy outcome was survival outcome. Other outcomes also evaluated were (1) symptomatic DVT, symptomatic pulmonary embolism, and all reported thromboembolic events, (2) adverse effects including major bleeding, minor bleeding, and thrombocytopenia.
Data extraction and study outcomes
Two reviewers (Y. Yu and F. Lan) independently extracted the data on basic study design, patient characteristics, study outcomes, and measures of study quality. A third investigator was consulted in case of disagreement (B. Zhang). Data for analysis were abstracted systematically from the published reports and included: (1) authors and year of publication, (2) the number of patients included in the study, (3) type and stage of lung cancer and other patient characteristics, (4) types, doses, and duration of anticoagulation therapy, (5) clinical outcomes, and (6) study design and Jadad score.
The methodological quality of each trial was evaluated by using the Jadad score,, a validated quality assessment instrument which incorporates randomization, blinding, and attrition to derive a score of 0 (very poor) to 5 (rigorous). Two reviewers independently assessed the quality of the included trials. Any divergence was resolved by discussion with a third reviewer to reach an agreement.
We measured the survival outcome by hazard ratio (HR) between the survival distributions. The log (HR) and its variance were extracted from the publications. When such data were not available directly, we extracted from Kaplan–Meier survival curves. Survival rates at some specified times were chosen and digitized by Get Data Graph Digitizer. We estimated the log rank statistic and its variance by using Parmar's methods. The individual HR point estimates were combined in STATA 12.0 (http://www.stata.com; Stata Corporation, College Station, TX), to obtain a pool HR estimate of the treatment effect. Conventionally, an HR <1 implied a survival benefit for the treatment arm. For dichotomous data, RRs and 95% confidence intervals (CIs) were calculated separately for each study to assess the incidence of outcomes by experimental group. An RR <1.0 was in favor of heparin therapy. We then pooled the RRs in STATA 12.0. The I2 statistics was used to quantify the heterogeneity across the studies, with I2 <25%, 25–75%, and >75% to represent the low, moderate, and high degree of heterogeneity, respectively. The HRs or RRs were pooled using a random effects model when I2 was >50% or a fixed effects model when I2 was <50%. Publication bias was estimated by the funnel plot for the primary outcome.
| > Results|| |
We found 9076 articles by search, and finally identified six studies eligible for our meta-analysis. The process of study selection was illustrated in [Figure 1].
A total number of 1393 participants were included, 753 patients in the heparin group, and 640 patients in the control group. The intervention was UFH in one study  and LMWH in 5 studies.,,,, Four studies reported survival outcomes. The details of the study characteristics are described in [Table 1]. The Begger's funnel plot and Begger's test were conducted to assess the publication bias. Statistical results did not demonstrate publication bias (P > 0.05 for all).
Across all eligible studies, according to a fixed-effects model, heparin had a discernible effect on survival in lung cancer patients with a calculated HR of 0.71 (95% CI 0.60–0.84; I2 = 42.0%) as described in [Figure 2]. A further pool estimate of the SCLC subgroup showed significant survival benefit (HR 0.72; 95% CI 0.59–0.87; I2 = 47.4%). We also performed a subgroup analysis of the limited-stage SCLC group in the fixed-effects model and identified substantially improvement in survival (HR 0.57; 95% CI 0.43–0.77; I2 = 0; [Figure 3]).
|Figure 2: The effect of heparin therapy on survival in patients with lung cancer|
Click here to view
|Figure 3: The effect of heparin therapy on survival in patients with small cell lung cancer|
Click here to view
There were 19 thromboembolic events among the 529 patients who received heparin therapy and 34 events in 404 patients in the control group. According to a fixed-effects model, there was a significant difference in thromboembolic events between the two groups (RR 0.46; 95% CI 0.27–0.80; I2 = 0%; [Table 2]).
|Table 2: Impact of heparin therapy on venous thromboembolism and safety outcomes in patients with lung cancer|
Click here to view
Based on four studies,,,, bleeding occurred in 42 of 534 (7.9%) patients in the heparin group versus 25 of 413 (6.1%) patients in the control group. In the fixed-effects model, LMWH use did not increase either bleeding (RR 1.53; 95% CI, 0.96–2.45; I2 = 6.2%; [Table 2]) or major bleeding complications (RR 1.43; 95% CI, 0.59–3.45; I2 = 0%; [Table 2]). Major bleeding was defined as bleeding which was fatal, requiring transfusion of two units of packed red cells, or associated with a decrease in hemoglobin of 20 g/L (e.g., retroperitoneal, intracranial, and hemoptysis).
In the three studies that reported thrombocytopenia, 78 of 335 (23.3%) patients in heparin group experienced a thrombocytopenia complication, compared with 95 of 332 (28.6%) in control group. According to a fixed-effects model, no significant difference was seen (RR 0.86; 95% CI, 0.66–1.12; I2 = 13.7%; [Table 2]).
| > Discussion|| |
The results of our meta-analysis indicated that administration of heparin (mainly LMWH) as primary thromboprophylaxis for lung cancer patients without indication for anticoagulants is associated with statistically significant survival benefit, particularly in limited-stage SCLC. A significant reduction in thromboembolic events was observed with the heparin therapy while the risk for bleeding, major bleeding, and thrombocytopenia is not significantly increased compared with the control arm.
So far several meta-analysis studies have investigated the role of heparin played in cancer treatment. Akl et al. focused their meta-analysis on 5 five RCTs that compared heparin-treated cancer patients with a control group in 2008 and showed a survival advantage of heparin in cancer patients. They performed a subgroup analysis of SCLC patients in two RCTs and suggested a higher benefit in patients with limited SCLC. In the two RCTs, Lebeau et al. explored the effect of UFH while Altinbas et al. combined LMWH with chemotherapy, and they both observed a discernible effect on overall survival. Our current meta-analysis has included two new studies compared with Akl's meta-analysis. The ABEL study enrolled patients with limited-stage SCLC and reported a significant overall survival advantage in the group assigned to LMWH, although the trial included only 38 patients. Whereas the study by van Doormaal did not show a survival benefit of nadroparin in patients with NSCLC. Zhang et al. also conducted a systematic review addressing the same question as our review. They calculated pooled relative risk (RRs) at 6 months, 1 year, and 2 years, whereas we calculated pooled HRs, which represents instantaneous rate and may be more persuasive. This study has shown that patients with limited-stage SCLC may benefit most from the heparin therapy.
Factors that may impact survival analysis include the prognosis of the patients and stage of the disease. In the FAMOUS and MALT studies which aimed to evaluate the impact of LMWH on cancer survival, the subgroup of patients with a prior life expectancy experienced a superior survival benefit., We also confirmed that limited-stage SCLC patients gain a superior survival advantage from heparin therapy than patients with extensive SCLC. Besides, whether the patients with cancer can benefit from heparin therapy depends on tumor types since VTE risk varies among different histological types of cancer.,, The highest risk of VTE was observed among patients with cancers of the pancreas, brain, and lung  as a result the decrease in VTE is most apparent among pancreatic and lung cancer., Thus, VTE prophylaxis may be preferred in these specific populations. In addition, the optimal dose, the type, and the duration of the treatment with LMWH or UFH remain inconclusive. For example, a recent retrospective study demonstrated that LMWH usage for more than 4 months increased risk for OS and PFS significantly in SCLC cases with comparison to LMWH usage for <4 months while there was not any significant difference between the duration of 4–6 months and more than 6 months. Thus, further studies aimed at additional heparin therapy to standard cancer treatment in lung cancer patients are warranted.
It is convincingly demonstrated that the survival benefit might at least in part attribute to a decrease in venous thromboembolic events. However, there is a substantial body of evidence showing that heparin has advantages beyond just the prevention and treatment of VTE. We speculate that the antitumor effects, anti-angiogenic effects, and immunomodulatory effects of heparin may also deliver survival benefit.,,
The major concern for using heparin is its potential bleeding risk. Other potential disadvantages, including health-care costs and patient discomfort from daily subcutaneous injections, should also be valued. Based on the results of the current meta-analysis, LMWH increased the risk of major bleeding  while some studies reported no apparent increase in major bleeding., Although both bleeding and major bleeding complications were not significantly increased by the heparin treatment in our meta-analysis, bleeding complication, especially major bleeding, must be handled cautiously owing to its lethality. Thence, further studies are needed to define risk stratification of VTE, bleeding, and other complications to highlight which patients should receive prophylaxis. Cost-effectiveness analysis should be appraised as well since most of the studies did not report hospitalization rate and cost.
Several limitations of our study should be noted. First of all, it is still not known whether the addition of heparin has similar effects in different lung cancer type due to a rather small number of studies. In our meta-analysis, only one included study was eligible for the analysis of NSCLC. Hence, the data were insufficient to reveal a statistically significant potential benefit. Further powered studies are required. Second, we cannot rule out that different dose, duration, and type of heparin may have different effects as no adequate information was available. Third, the number of patients included in the analyzed studies was relatively small, so the inclusion of future trials might change the results. These limits decreased powerfulness of our results.
| > Conclusion|| |
Our systematic review and meta-analysis reveal that administration of heparin (mainly LMWH) as primary thromboprophylaxis for lung cancer patients without indication for anticoagulants is associated with apparent survival benefit, particularly in limited-stage SCLC. Thromboembolic events were reduced by the intervention of heparin while the risk for bleeding and major bleeding was not significantly increased and neither the rate of thrombocytopenia.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| > References|| |
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al.
Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014;64:252-71.
Alifano M, Benedetti G, Trisolini R. Can low-molecular-weight heparin improve the outcome of patients with operable non-small cell lung cancer? An urgent call for research. Chest 2004;126:601-7.
Khorana AA. Malignancy, thrombosis and Trousseau: The case for an eponym. J Thromb Haemost 2003;1:2463-5.
Blom JW, Doggen CJ, Osanto S. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. J Vasc Surg 2006;43:866.
Danilenko-Dixon DR, Heit JA, Silverstein MD, Yawn BP, Petterson TM, Lohse CM, et al.
Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or post partum: A population-based, case-control study. Am J Obstet Gynecol 2001;184:104-10.
Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-50.
Lee AY. Cancer and thromboembolic disease: Pathogenic mechanisms. Cancer Treat Rev 2002;28:137-40.
Noble S. The challenges of managing cancer related venous thromboembolism in the palliative care setting. Postgrad Med J 2007;83:671-4.
Robert F. The potential benefits of low-molecular-weight heparins in cancer patients. J Hematol Oncol 2010;3:3.
Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Haemost 1998;80:10-23.
Mellema WW, Smit EF, Dingemans AM. Low molecular weight heparins in the treatment of lung cancer. Expert Opin Investig Drugs 2011;20:1517-22.
Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C, et al.
Subcutaneous heparin treatment increases survival in small cell lung cancer. “Petites Cellules” Group. Cancer 1994;74:38-45.
Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, et al.
A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004;2:1266-71.
Lecumberri R, López Vivanco G, Font A, González Billalabeitia E, Gúrpide A, Gómez Codina J, et al.
Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: Results from the ABEL study. Thromb Res 2013;132:666-70.
van Doormaal FF, Di Nisio M, Otten HM, Richel DJ, Prins M, Buller HR. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol 2011;29:2071-6.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.
Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12.
Moher D, Jadad AR, Nichol G, Penman M, Tugwell P, Walsh S. Assessing the quality of randomized controlled trials: An annotated bibliography of scales and checklists. Control Clin Trials 1995;16:62-73.
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
Sutton AJ, Duval SJ, Tweedie RL, Abrams KR, Jones DR. Empirical assessment of effect of publication bias on meta-analyses. BMJ 2000;320:1574-7.
Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, et al.
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: A randomised, placebo-controlled, double-blind study. Lancet Oncol 2009;10:943-9.
Haas SK, Freund M, Heigener D, Heilmann L, Kemkes-Matthes B, von Tempelhoff GF, et al.
Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost 2012;18:159-65.
Akl EA, van Doormaal FF, Barba M, Kamath G, Kim SY, Kuipers S, et al.
Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: A cochrane systematic review. J Exp Clin Cancer Res 2008;27:4.
Zhang J, Zhang YL, Ma KX, Qu JM. Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants: A systematic review and meta-analysis. Thorax 2013;68:442-50.
Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, et al.
The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-5.
Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, et al.
Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004;22:1944-8.
Lazo-Langner A, Goss GD, Spaans JN, Rodger MA. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 2007;5:729-37.
Sanford D, Naidu A, Alizadeh N, Lazo-Langner A. The effect of low molecular weight heparin on survival in cancer patients: An updated systematic review and meta-analysis of randomized trials. J Thromb Haemost 2014;12:1076-85.
Kuderer NM, Khorana AA, Lyman GH, Francis CW. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: Impact on survival and bleeding complications. Cancer 2007;110:1149-61.
Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: A systematic review and meta-analysis. PLoS Med 2012;9:e1001275.
Ben-Aharon I, Stemmer SM, Leibovici L, Shpilberg O, Sulkes A, Gafter-Gvili A. Low molecular weight heparin (LMWH) for primary thrombo-prophylaxis in patients with solid malignancies – Systematic review and meta-analysis. Acta Oncol 2014;53:1230-7.
Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 2013;119:648-55.
Altinbas M, Dikilitas M, Ozkan M, Dogu GG, Er O, Coskun HS. The effect of small-molecular-weight heparin added to chemotherapy on survival in small-cell lung cancer – A retrospective analysis. Indian J Cancer 2014;51:324-9.
Bobek V, Boubelik M, Fiserová A, L'uptovcová M, Vannucci L, Kacprzak G, et al.
Anticoagulant drugs increase natural killer cell activity in lung cancer. Lung Cancer 2005;47:215-23.
Mousa SA, Mohamed S. Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: Anti-cancer efficacy. Oncol Rep 2004;12:683-8.
Bobek V, Kovarík J. Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother 2004;58:213-9.
Phan M, John S, Casanegra AI, Rathbun S, Mansfield A, Stoner JA, et al.
Primary venous thromboembolism prophylaxis in patients with solid tumors: A meta-analysis. J Thromb Thrombolysis 2014;38:241-9.
Che DH, Cao JY, Shang LH, Man YC, Yu Y. The efficacy and safety of low-molecular-weight heparin use for cancer treatment: A meta-analysis. Eur J Intern Med 2013;24:433-9.
[Figure 1], [Figure 2], [Figure 3]
[Table 1], [Table 2]